GlassScriptPhysician profile
Brian A Schlesinger
NPI 1013018944
$1,885.76
in general payments reported to CMS, 2019-2025
12 companies · $625 in 2025
The $625 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.51 · 2022: $202 · 2023: $396 · 2024: $577 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,284.41 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Paratek Pharmaceuticals, INC. | $155.12 | 2022-2023 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $86.63 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $75.50 | 2023-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $47.80 | 2025 | |
| Sanofi-Aventis U.S. LLC | $44.27 | 2021-2025 | |
| Glaxosmithkline, LLC. | $44.06 | 2024-2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $43.88 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.30 | 2025 | Caplyta |
| Lilly USA, LLC | $29.70 | 2025 | Mounjaro, Zepbound |
| Alk-Abello, INC | $23.13 | 2025 | Ragwitek, Odactra, Grastek |
| Takeda Pharmaceuticals U.S.A., INC. | $16.96 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Schlesinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.